» Articles » PMID: 17441925

Immunotherapy for Metastatic Renal Cell Carcinoma

Overview
Journal BJU Int
Specialty Urology
Date 2007 Apr 20
PMID 17441925
Citations 9
Authors
Affiliations
Soon will be listed here.
Citing Articles

The categorizations of vasculogenic mimicry in clear cell renal cell carcinoma unveil inherent connections with clinical and immune features.

Geng B, Liu W, Wang J, Zhang W, Li Z, Zhang N Front Pharmacol. 2024; 14:1333507.

PMID: 38178861 PMC: 10765515. DOI: 10.3389/fphar.2023.1333507.


Biomarkers of Prognosis and Efficacy of Anti-angiogenic Therapy in Metastatic Clear Cell Renal Cancer.

DAniello C, Berretta M, Cavaliere C, Rossetti S, Facchini B, Iovane G Front Oncol. 2020; 9:1400.

PMID: 31921657 PMC: 6917607. DOI: 10.3389/fonc.2019.01400.


Engrailed-2 is down-regulated but also ectopically expressed in clear cell renal cell carcinoma.

Lai C, Pan B, Luo Y, Liang W, Chen J, Ye D Mol Biol Rep. 2014; 41(6):3651-7.

PMID: 24532139 DOI: 10.1007/s11033-014-3229-z.


State of the science: an update on renal cell carcinoma.

Jonasch E, Futreal P, Davis I, Bailey S, Kim W, Brugarolas J Mol Cancer Res. 2012; 10(7):859-80.

PMID: 22638109 PMC: 3399969. DOI: 10.1158/1541-7786.MCR-12-0117.


Treatment selection in metastatic renal cell carcinoma: expert consensus.

Escudier B, Szczylik C, Porta C, Gore M Nat Rev Clin Oncol. 2012; 9(6):327-37.

PMID: 22473096 DOI: 10.1038/nrclinonc.2012.59.